Early oral contraceptive use and breast cancer: results of another case-control study. by McPherson, K. et al.
Br. J. Cancer (1987), 56, 653-660
© The Macmillan Press Ltd., 1987
Early oral contraceptive use and breast cancer: Results of another
case-control study
K. McPherson', M.P. Vessey', A. Neill,*, R. Doll2, L. Jones' & M. Roberts3
'Department ofCommunity Medicine and General Practice, Radcliffe Infirmary, Oxford; 2Imperial Cancer Research Fund,
Cancer Epidemiology and Clinical Trials Unit, Oxford and 3Breast Screening Clinic, Springwell House, Edinburgh, UK.
Summary We report the results of a case-control study of oral contraceptive use and breast cancer
conducted in London, Oxford and Edinburgh between 1980 and 1984. One thousand one hundred and
twenty-five women aged 16-64 years with newly diagnosed breast cancer and a like number of matched
controls were interviewed and asked about their past use of oral contraceptives (OCs). Among women aged
45 years or more at diagnosis there was no evidence of an association between OC use and breast cancer.
Among the 351 pairs of women aged under 45 years at diagnosis there was a significantly elevated risk
associated with increasing duration of use before first full term pregnancy (relative risk for 4+ years use
versus never use=2.6, 95% confidence limits, 1.3-5.4). Since this result is at variance with the findings in
some other studies we have investigated the nature of this association with particular emphasis on possible
bias, pill type and a latent effect.
The possible role of oral contraceptives (OC) in the aetiology
of breast cancer has been investigated in numerous
epidemiological studies. Most of these studies have indicated
that OC use is not associated with any change in breast
cancer risk, but there are some residual anxieties about this
broad conclusion. In particular, a publication by
Paffenberger et al. (1977) suggested the possibility of an
adverse effect of OC use before first term pregnancy which
was subsequently supported by a study by Pike et al. (1981).
This suggestion, although by no means confirmed, is of
particular interest because age at first term pregnancy is
known to influence the risk of breast cancer (McMahon et
al., 1973) and in consequence some have argued (Day, 1984)
that the first term pregnancy may protect against early stage
carcinogenesis. Others have suggested that exposure to
oestrogens before first term pregnancy may be an important
part of the aetiological process (Korenman, 1980). Drife
(1981), in turn, has hypothesised that irreversible changes in
breast tissue associated with pregnancy activate progesterone
receptors which then enable the oestrogen exposure to be
opposed by circulating progesterone.
The role of OC exposure before first term pregnancy is
consequently receiving much epidemiological attention. This
is usually in the form of case control studies since cohort
studies, which were mostly started in the late sixties, do not
include many women who used OC's before first term
pregnancy because such use is a relatively recent practice
(Bone, 1979). The results from these studies are conflicting
and confusing (McPherson & Drife, 1986). Some appear to
suggest an increased risk associated with long term use
before first term pregnancy or before age 25, while others do
not. Several possible reasons have been suggested for this,
including bias in the selection of controls, bias in recall of
OC history and selection bias of cases associated with earlier
diagnosis among women who have regular breast
examinations. As well as these biases there is the possibility
of a differential effect of various OC formulations taken at
different times in a womans life and the possibility that there
may be a long latent period before the manifestation of any
possible effect.
In principle any of these factors could be responsible for
the apparently conflicting results. It is, however, difficult to
establish with any certainty which actually are, for it is
usually only possible to suggest, with varying degrees of
plausibility, possible explanations for the different results.
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We report here the results of a case control study conducted
between 1980 and 1984 which was a continuation of a
similar (but negative) study conducted between 1968 and
1980 (Vessey et al., 1983). This enabled us to investigate
some of these possible factors with unusual rigour.
Since 1980 the most relevant studies investigating the
association between early OC use and breast cancer have
been the case control studies of Pike et al. (1983), Harris et
al. (1982), Rosenberg et al. (1984), Vessey et al. (1982),
Stadel et al. (1985), Meirik et al. (1986), Paul et al. (1986)
and Miller et al. (1986). Pike et al. (1981), from Los Angeles,
reported an elevated risk for use before first term pregnancy
among women under the age of 33, but this was not
confirmed by the study of Vessey and colleagues (1982).
Indeed such use appeared, in the latter study, to be
protective, but not significantly so. A further extension of
Pike's study, published in 1983, appeared to show an
elevated risk associated with use before age 25 among
women under the age of 37. This, however, was inconsistent
with the results of the large American Cancer and Steroid
Hormone (CASH) group study published in 1985 (Stadel et
al., 1985). The CASH group found no significant increase in
risk either for use before age 25 or for use before first term
pregnancy among women under 37 or, in response to the
publication of the interim results of the present study
(McPherson et al., 1983), under age 45. Harris et al. (1982)
reported an increased risk associated with use before first
term pregnancy in a small study, while Rosenberg and
colleagues (1984) found no increased risk except in a
subgroup exposed for a long period while young, more than
ten years before diagnosis. Results from a small study in
Southern Sweden (Olson et al., 1985) reported an increased
risk associated with starting to use the pill at young ages.
However the controls were not interviewed in the same
manner as the cases, leading to the possibility of bias.
Most recently, three additional studies have been
published, one from Sweden and Norway (Meirik et al.,
1986), another from New Zealand (Paul et al., 1986) and one
from North America (Miller et al., 1986). The Scandinavian
study shows an increased risk associated with very long term
use in Sweden, but not in Norway and not necessarily before
first term pregnancy while the new Zealand study shows no
evidence of any association at any period. The US study,
based on a matched comparison of women under age 45
shows only a suggestion of an elevated risk associated with 5
or more years use before first term pregnancy.
Clearly since breast cancer is the commonest cancer
among women (OPCS, 1982) and since OC use is a very
popular method of contraception (Kay, 1986) particularly in
the last decade or so amongst the young, the investigation of
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any association is extremely important. However the
evidence is so conflicting that assertions about the true
nature of any association are presently unhelpful. We report
here the results of our investigation in the hope that other
studies can test the hypotheses we suggest and, if sustained,
that a sensible method for pooling the results of all the
studies can evolve.
Subjects and methods
Since September 1980, ever-married women aged 16-59 years
newly presenting with breast cancer at six London hospitals
or at the John Radcliffe or Churchill Hospitals in Oxford,
and those aged 45-64 diagnosed as having breast cancer at
the screening clinic in Edinburgh, have been interviewed by
specially trained nurses. (Most of the analyses presented here
concern women under the age of 45 explicitly, and therefore
do not include the Edinburgh sample). For each patient, a
married control (within the same 5 year age group) was
selected from female patients in the same hospital who had
certain medical or surgical conditions that were thought not
to be associated with contraceptive practice. The controls in
Edinburgh were randomly selected women who had been
normal on screening. Each case and control was asked
questions in a like manner by the same interviewer about
their medical, gynaecological, obstetric, menstrual, contra-
ceptive and social histories. The emphasis of this study, as
opposed to our previous study (Vessey et al., 1982) was,
however, changed a little from being largely concerned with
the possible effects of contraception to being primarily
concerned with fertility and its role in breast cancer
aetiology. However, since fertility cannot be directly
measured by interview techniques we again sought details of
contraceptive practices, and obstetric events as well as
conception intentions. In the previous (but not the present)
study, controls were matched with cases for parity as well as
age and hospital.
When, in 1983, the paper from Los Angeles was published
(Pike et al., 1983) suggesting an increased risk of breast
cancer among young women associated with OC use before
age 25, we examined our accumulated data to test Pike
et al.'s hypothesis. The findings were published as a letter
(McPherson et al., 1983). Recruitment was completed at the
end of 1984 and we report here the results of the final
analyses of this study concentrating largely on cases and
controls recruited when under 45 years of age. We also
investigate several hypotheses suggested by the diverse
literature on early OC use and its possible association with
breast cancer. The nature of this analysis is such that
conclusions must be tentative because some of these
hypotheses are themselves suggested by our data. There are
many possible explanations which the diversity of the
epidemiological results suggest, and this work can serve to
point in plausible directions.
We use standard methods for the analysis of matched case
control studies (Breslow & Day, 1980), adjusting for
confouding variables where necessary. When standardizing
for the effect of age at first term birth, nullipara were
analysed in a separate stratum.
Results
General epidemiologicalfindings
Table I shows the distribution of important characteristics of
cases and controls divided into two groups by age at
recruitment. As expected, in both groups a family history of
breast cancer, a history of benign breast disease and late age
at first term birth are more common among cases than
among controls. On the other hand an early menarche is no
more common among cases in either age group.
Total OC use in various duration categories was almost
equally distributed between cases and controls but was much
less common in the older group than in the younger group.
The latter finding reflects the increasing popularity of OCs
particularly among the young, and the fact that OCs did not
become available in this country until the early 1960s; thus a
woman who was 45 in 1980 was already 25 or more when
OCs became available. The largest difference between the age
groups, however, is shown in the distribution of OC use
before first term pregnancy, including total use among
nulliparous women. Among the older group barely 3% had
any OC use before first term pregnancy while in the younger
group around 28% reported such use. As we have described
before from a subset of these data (McPherson et al., 1983),
there was an excess of OC use before first term pregnancy
among cases compared with controls, aged less than 45. The
percentages in each sub-group of OC use in the complete
data reported here differ by 2% at the most from those
given in our previous report. There was little difference
between the cases and controls in the use of OCs before age
25 and some slight suggestion that OC use only after the
first pregnancy is protective. There was no effect of OC use
after first pregnancy, with or without use before.
Table II shows the results of multiple logistic analysis of
total OC use by age group, both crude and after adjusting
for possible confouding effects. None of the relative risks is
statistically significant but there is a slight suggestion of an
increasing risk associated with very long term use in the
younger age group, when adjusted for confouding.
In Table III we show similar analyses for the under 45
year olds including only OC use before first term pregnancy.
In this instance the results indicate a significantly raised risk
associated with increasing duration of use. The x2 value for
linear trend (6.96) is highly significant statistically, (P<0.01).
Investigation ofpossible explanationsfor results
Since the results in the women aged under 45 years are
importantly different from those we have already published
from an earlier case control study (Vessey et al., 1982), and
from the results of the CASH study (Stadel et al., 1985) and
others, we investigated particular hypotheses which might
explain these differences. We regard it as being intrinsically
unlikely that bias in recall of OC history and bias in the
selection of controls could explain much of the difference
between our two studies because, for women under the age
of 45, they were conducted by the same interviewers in the
same hospitals using almost the same protocol for
interviewing and control selection, although matching for
parity was not undertaken in the more recent study. We
have, however, investigated both possibilities. First, Table IV
shows a break down of exposure before first term pregnancy
among our subjects according to whether they were
interviewed before the publication, in October 1983, of the
paper by Pike et al. (1983) which received much publicity, or
afterwards. Clearly for recall inaccuracy to be a cause of
bias, cases must recall their OC history either more or less
reliably than controls and this is most likely to happen when
there is considerable awareness of a possible association
between OCs and breast cancer. There is no evidence for this
effect in these data. Secondly we have investigated the
diagnoses of the controls selected in the earlier study and in
this study. Table V shows the categorization of these
diagnoses in the two studies. It is clear that there are some
differences in the control diagnoses, notably a higher
proportion of arthritis, other musculoskeletal disorders and
skin conditions in the second study. However, a comparison
between the exposure of these controls and their matched
cases reveals little evidence that the change in risk estimates
between the two studies is attributable to differences in the
diagnoses of the controls (Table VI). The excess of long term
use among cases is not confined to those matched with
controls with skin conditions, arthritis or musculoskeletal
problems.
We have also investigated the effect of many possible
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results. Well established risk factors which could be
associated with early OC use have been used in the
adjustments in the multivariate analysis. Other possible risk
factors like parity, smoking status and alcohol consumption
did not importantly confound the comparisons. The most
important confouding variable, not surprisingly, was age at
first term pregnancy and this is the main reason why the
adjusted relative risks in Table III are reduced. When we
stratified the data by age at first term birth the same kind of
association was found within each stratum.
Lastly, we investigated the possibility of a bias attributable
to more breast examination among OC users. In principle, if
women using OC's before first term pregnancy were more
inclined to examine their breasts for lumps than non users,
then, in the absence of any change in risk attributable to OC
use, a study such as ours might yield a positive association
Table I Characteristics of cases and controls, numbers and (%)
Age group Age group
<45 45+ <45 45+
Cases Controls Cases Controls Cases Controls Cases Coa-ltrols
Age at diagnosis
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
19 (5)
60 (17)
93 (26)
179 (51)
19 (5)
60 (17)
93 (26)
179 (51)
- - 248 (32)
-- 254 (33)
224 (29)
_ 38 (5)
248 (32)
254 (33)
224 (29)
38 (5)
351 351 774 774
Family history ofbreast cancer
Yes 35 (10)
No 316 (90)
351 351
17 (5) 78 (10) 52 (7)
334 (95) 696 (90) 722 (93)
774 774
Use ofother contraceptive methods
IUD 86 (25)
Cap 74 (21)
Sheath 261 (74)
Chemical 21 (6)
Safe period 51 (15)
Withdrawal 103 (29)
None 40 (11)
OC use beforefirst term pregnancy
No use 235 (67)
1-12 months 27 (8)
13-48 months 43 (12)
48+ months 46 (13)
351
104 (30) 52 (7)
74 (21) 216 (28)
239 (68) 493 (64)
27 (8) 61 (8)
48 (14) 87 (11)
106 (30) 293 (38)
39 (11) 95 (12)
273 (78) 753 (97)
26 (7) 9 (1)
29 (8) 9 (1)
23 (7) 3 (0)
351 774
History ofsurgeryfor benign breast disease
Yes 32 (9) 23 (7)
No 319 (91) 328 (93)
351 351
Age at menarche
Unknown
10
11
12
13
14
15
16+
Age atfirst term birth
Nulliparous
<20
21-24
25-28
29+
Menopausal status
Pre
Artificial
Natural
Total OC use
Never
1-4 years
4-12 years
12+ years
3 (1)
19 (5)
64 (18)
60 (17)
83 (24)
58 (17)
36 (10)
28 (8)
351
35 (10)
54 (15)
96 (27)
98 (28)
68 (19)
351
325 (93)
25 (7)
1 (0)
351
111 (32)
117 (33)
102 (29)
21 (6)
1 (0)
28 (8)
70 (20)
71 (20)
64 (18)
56 (16)
37 (11)
25 (3)
351
37 (11)
95 (27)
106 (30)
81(23)
32 (9)
351
103 (13)
671 (87)
774
9 (1)
22 (3)
125 (16)
109 (14)
181 (23)
179 (23)
90 (12)
59 (8)
744
97 (13)
68 (9)
219 (28)
207 (27)
183 (24)
774
89 (11)
685 (89)
774
3 (0)
29 (4)
112 (14)
114 (15)
158 (20)
175 (23)
87 (11)
96 (12)
774
87 (11)
112 (14)
248 (32)
196 (25)
131 (17)
774
298 (85) 306 (40) 239 (31)
50 (14) 118 (15) 208 (27)
3 (1) 350 (45) 327 (42)
351 774 774
122 (35)
120 (34)
89 (25)
20 (6)
590 (76)
101 (13)
70 (9)
13 (2)
567 (73)
125 (16)
59 (8)
23 (3)
i) Nulliparous women (total use)
No use 9 (26) 10 (27)
1-12 months 5 (14) 7 (19)
13-48 months 6 (17) 9 (24)
48 + months 15 (43) 11 (30)
35 ' 37
ii) Parous women
No use
1-12 months
13-48 months
48 + months
226 (72)
22 (7)
37 (12)
31 (10)
263 (84)
19 (6)
20 (6)
12 (4)
82 (85)
7 (7)
5 (5)
3 (3)
97
671 (99)
2 (0)
4 (1)
0 (0)
79 (91)
3 (3)
5 (6)
0 (0)
87
679 (99)
5 (1)
1 (0)
2 (0)
316 314 677 687
OC use only afterfirst term pregnancy
No use
1-12 months
13-48 months
48 + months
OC use before age 25
No use 2
1-12 months
13-48 months
48 + months
Time sincefirst used OCs
Never used l
0-4 years
4-8 years
8-12 years
12-15 years
15-20 years
20+ years
227 (65)
32 (9)
32 (9)
60 (17)
351
201 (57)
45 (13)
35 (10)
70 (20)
351
227 (65) 222 (63)
42 (12) 50 (14)
50 (14) 54 (15)
32 (9) 25 (7)
351 351
111 (32)
4 (1)
24 (7)
78 (22)
63 (18)
61 (17)
10 (3)
122 (35)
10 (3)
26 (7)
55 (16)
49 (14)
75 (21)
14 (4)
611 (79)
51 (7)
41 (5)
71 (9)
774
773 (100)
1 (0)
0 (0)
0 (0)
774
590 (76)
5 (1)
14 (2)
27 (3)
34 (4)
86 (11)
18 (2)
583 (75)
70 (9)
49 (6)
72 (9)
774
765 (99)
5 (1)
4 (1)
0 (0)
774
567 (73)
8 (1)
10 (1)
23 (3)
30 (4)
92 (12)
44 (6)
351 351 774 774
70 (9)
222 (29)
486 (63)
65 (8)
97 (13)
273 (35)
135 (17)
758 (98)
8 (1)
6 (1)
2 (0)
774
351 351 774 351 351 774 774 774656 K. McPHERSON et al.
Table II Effect of total duration of OC use on breast cancer risk
Relative risk
Age <45 Age 45+
Adjusteda Adjusteda
Total duration (confidence limits) (confidence limits)
ofOC use Unadjusted (95%) Unadjusted (95%)
Never 1.00 1.00 1.00 1.00
<4 years 1.08 1.12 (0.75-1.67) 0.79 0.78 (0.58-1.05)
4-12 years 1.22 1.20 (0.78-1.84) 1.01 1.05 (0.70-1.59)
12+ years 1.17 1.78 (0.82-3.87) 0.78 0.84 (0.39-1.80)
32 (Heterogeneity) 1.20 2.30 3.06 3.11
aAdjusted for age at first term birth, age at menarche, menopausal status, history of
benign breast disease and family history of breast cancer. Cigarette smoking and social
class were not confounding variables.
Table III Relative risk of breast cancer associated
with oral contraceptive use before first term pregnancy
in those aged <45 years
Relative risk
Adjusteda
Duration OC (confidence limits)
use Unadjusted (95%)
Never 1.00 1.00
1-12 months 1.23 1.02 (0.5-1.9)
13-48 months 2.42 1.97 (1.0-3.8)
48+ months 3.19 2.59 (1.3-5.4)
aAdjusted for age at first term birth, age at
menarche, menopausal status, history of benign breast
disease and family history of breast cancer.
%2 (heterogeneity) =8.69 P<0.05.
%2(linear trend)=6.96 P<0.01.
Table IV Oral contraceptive use before first term
pregnancy numbers and (%)
Cases
Duration OC use
(mths) Pre Oct. 1983 Post Oct. 1983
Never 175 (68) 60 (64)
1-12 20 (8) 7 (7)
13-48 29 (11) 14 (15)
48+ 33(13) 13(14)
257 94
Controls
Duration OC use
(mths) Pre Oct. 1983 Post Oct. 1983
Never 189 (79) 84 (74)
1-12 14 (6) 12 (11)
13-48 18 (8) 11(10)
48+ 17 (7) 6 (5)
238 113
because, on average, the age at diagnosis might be younger
for OC users than for non users (Mant et al., 1987). We
asked all our subjects whether they had practiced breast self
examination (BSE), whether they had been taught the
technique and whether they had a history of medical breast
examination before recruitment. Table VII shows that BSE
was no more common among OC users than among non
users; however, among cases, OC users were slightly more
likely to have been taught BSE than non users. There was
no evidence that OC users were more likely to have their
Table V Diagnosis ofcontrols - age less than 45. Numbers and (%)
First study Secondstudy
Diagnosis 1968-1980 1980-1984
Benign neoplasms 42 (5) 4 (1)
Thyroid/other endocrine disorder 23 (3) 0 (0)
CNS/eye/ear disorder 67 (8) 24 (7)
Appendicitis/digestive disorder
hernia/oral cavity disorder 163 (19) 80 (23)
Kidney disorder/cystitis/renal
calculus 87 (10) 23 (7)
Skin disorder 42 (5) 43 (12)
Arthritis/musculoskeletal disorder 119 (14) 74 (21)
Symptoms, ill defined
conditions 130 (15) 59 (17)
Trauma 74 (9) 16 (5)
Other conditions 108 (13) 28 (8)
855 100 351 100
breasts medically examined than non users. While we have
shown elsewhere that the practice of taught BSE has a
modest beneficial effect on breast cancer stage at diagnosis
(Mant et al., 1987) the difference reported here is not
statistically significant and seems to be too small to be of
importance.
Other possible explanations for our findings include a
change in OC composition, or a delayed (or latent) effect in
the manifestation of an OC effect or chance.
OC type Since in the present study use of around 30 OC
types was reported, with two synthetic oestrogen components
and eight different progestogens, each in varying doses, we
considered that the establishment of a plausible hypothesis
concerning pill type and its association with breast cancer
would be both difficult and insecure. We therefore decided
simply to examine the data by accumulating months of OC
use before first term pregnancy in the cases and controls
according to reported pill brand. We then ranked the pill
brands according to the difference in accumulated months
among cases and among controls. In this way we were able
to establish which pill brands were making the greatest
contribution to the effect seen in Table III. Two points must
be emphasized; first it is known that recollection of pill
brand is far from reliable (Coulter et al., 1986) and second
the individual pill brand differences are heavily affected by
sampling error because they are based on small numbers.
Indeed, an important proportion of subjects could not
remember sufficiently reliably which brand they had used.
The results are shown in Table VIII.
The most obvious deducation from this table is that (in
the light of the hypotheses mentioned) E-O (ethinylEARLY ORAL CONTRACEPTIVES AND BREAST CANCER 657
Table VI OC use before first term pregnancy among controls, by diagnosis, and matched cases.
(Second study only)
OC use beforefirst term pregnancy (months)
Diagnosis Never 1-12 13-48 48+ Total
Benign neoplasms Cases 4 0 0 0 4 Benign neoplasms Controls 3 0 1 0 4
CNS/eye/ear disorder Cases 22 1 13 12 24
Appendicitis/digestive disorder/hernia/oral Cases 53 8 10 9 80
cavity disorder Controls 58 7 10 5 80
Kidney disorder/cystitis/renal calculus Cases 10 5 3 5 23 Controls 17 0 4 2 23
Skin disorder Cases 27 3 9 4 43
Controls 33 1 3 6 43
Arthritis/musculoskeletal disorder Cases 50 4 5 15 74
Symptoms illdefnedconitiCases 40 5 9 5 59 Symptoms, ill defined conditions Controls 42 8 4 5 59
Cases 12 1 1 2 16 Trauma Controls 12 2 2 0 16
Other conditions Cases 21 0 3 4 28 Other conditions ~~~~Controls 23 4 0 1 28
Total Cases 235 27 43 46 351
Controls 273 26 29 23 351
Table VII Prior breast examination. Numbers of women and (%),
cases and controls under 45 years of age, according to ever use of
OCs before first term pregnancy
OC use beforefirst term pregnancy
Cases Controls
Never Ever Never Ever
(i) Practice BSE
NO 95(40) 49(42) 93 (34) 32(41)
YES 140(60) 67(58) 180(66) 46(59)
235 116 273 78
(ii) Properly taught
NO 127(54) 53(46) 149(55) 41(53)
YES 108(46) 63(54) 124(45) 37(47)
235 116 273 78
(iii) History ofmedical examination ofbreasts
NO 150(64) 75(65) 191 (70) 57(73)
YES 85(36) 42(36) 82(30) 21(27)
235 116 273 78
oestradiol) pills are associated with large differences between
cases and controls if they were marketed before the early
1970s. Otherwise ME (mestranol) pills are represented in all
ranks in the table whether or not they were recently
available. Recently available E-O pills, particularly those
with a low dose, do not have high ranks in Table VIII.
When we pursued this observation using multiple logistic
analysis, we found the relative risks shown in Table IX
indicating a significant difference in the effects of the two
synthetic oestrogens. First, the x2 (ldf) for linear trend for
E-O pills was 6.93 which is of a similar magnitude to that for
all pills (see Table III) in spite of smaller numbers exposed.
The x2 for linear trend for ME pills was 0.04. This indicates
no trend with increasing exposure for ME pills as opposed to
a highly significant trend for E-O pills. Hence if one simply
tests the difference in relative risk estimate associated with 4
or more years use before first pregnancy for the two pill
types then 2.62 is significantly greater than 0.57, (Z=2.12,
P<0.05). On the other hand a similar test of exposure for
13-48 months (2.16 vs. 1.46) is not significant.
Latency In order to investigate the existence of a possible
latent effect, we excluded successively OC use before first
term pregnancy within 2,4,.. .,20 years of diagnosis (or the
equivalent date for controls) in the accumulation of total
duration of OC use. Thus, for example, in excluding all OC
use within 10 years of diagnosis, only use before first
pregnancy and before that period was used as a measure of
the amount of relevant exposure. If a short period of
observation after exposure is a cause of underestimation of
relative risk in the usual analysis of case control studies, then
an analysis such as this should result in a progressive change
in relative risk estimates as more recent use is excluded
(McPherson et al., 1986).
The results of this analysis are shown in Table X from
which it can be seen that use of all OCs is not associated
with a systematic increase in relative risk with increasing
time since exposure. However, dividing the data into the two
categories of OCs shown in Table IX yields a different set of
results. These are also shown in Table X. It can be seen that
for E-O OCs the rise in estimated relative risk starts at
about 4 years before diagnosis and reaches a maximum at 10
years. Since many of the more common E-O OCs were not
introduced until 1970 or later the analyses after this period
are most unreliable. For ME OCs the pattern indicates if
anything a protective effect associated with long term use, a
long time before diagnosis. This trend is, however, not
significant. (Individual tabulations of numbers of cases and
controls are not given here but can be obtained on request
from the authors).
Nothing can be said from these data, if there is a long
latent period, about the particular influence of modern low
dose pills on breast cancer risk because these pills were not
introduced commonly until the mid 1970's. Table VIII does,
however, suggest that the only E-O pills with a low rank are
also pills introduced recently whether or not they were high
or low dose.
Discussion
The aetiology of breast cancer is known to have an658 K. McPHERSON et al.
Table VIII Accumulated OC use before first term pregnancy by individual pill brand
Cases Controls Difference
Oestrogen Progestogen Year of
Brand (g) (mg) Women Months Women Months Women Months introduction
NK 35 890 22 355 13 535 -
Ovulen 50 E-O 50 EDD 1.0 7 512 1 11 6 501 1970
Gynovlar E-O 50 NEA 3.0 14 504 3 76 11 428 1964
Minovlar E-O 50 NEA 1.0 24 968 17 637 7 331 1969
Minilyn E-O 50 LYN 2.5 9 369 3 45 6 324 1970
Anovlar E-O 50 NEA 4.0 7 276 2 29 5 247 1962
Norlestrin E-O 50 NEA 2.5 1 145 0 0 1 145 1964
Eugynon 30 E-O 30 LNG 0.25 12 343 7 208 5 135 1973
Orthonovin 1/50 M 50 NET 1.0 4 250 3 135 1 115 1970
Lyndiol M 150 LYN 5.0 2 77 1 6 1 71 1963
Lyndiol 2.5 M 75 LYN 2.5 3 67 0 0 3 67 1965
Norgeston - LNG 0.03 1 29 0 0 1 29 1979
Feminor M 100 NEL 5.0 1 23 0 0 1 23 1968
Conovid M 75 NEL 5.0 1 17 0 0 1 17 1961
Neogest - LNG 0.0375 1 15 0 0 1 15 1974
Ovran 30 E-O 30 LNG 0.25 2 89 1 86 1 3 1976
Serial 28 E-O 100 MA 1.0 0 0 1 9 -1 -9 1966
Norinyl-I M 50 NET 1.0 7 367 10 383 -3 -16 1966
Microgynon-30 E-0 30 LNG 0.15 4 180 9 205 -5 -25 1974
Eugynon 50 E-O 50 LNG 0.25 3 53 3 81 0 -28 1973
Orthonovin 1/80 M 80 NET 1.0 1 30 1 59 0 -29 1968
Orthonovin M 100 NET 2.0 1 23 1 58 0 -35 1967
Volidan E-O 50 MA 4.0 0 0 1 36 -1 -36 1963
Ovranette E-O 30 LNG 0.15 3 73 2 125 1 -52 1974
Ovysmen E-0 35 NET 0.5 0 0 1 59 -1 -59 1976
Ovulen M 100 EDD 1.0 12 239 8 304 4 -65 1964
Ovran E-O 50 LNG 0.25 2 32 4 133 -2 -101 1973
Note - For pills containing dl-norgestrel, the doses have been given in levenorgestrel equivalent.
Oestrogen E-O - Ethinyloestradiol; M - Mestranol.
Progestogen NET - Norethisterone; NEL - Norethynodrel; NEA - Norethisterone acetate; EDD - Ethynodiol
diacetate; LNG - Levonorgestrel; MA - Megestrol acetate; LYN - Lynestrenol.
Table IX Adjusted relative risksa by type of synthetic oestrogen
Months use
Type of beforefirst Relative 95%
oestrogen term pregnancy risk Confidence limit
E-O Never 1.00
1-12 1.21 0.50-2.93
13-48 2.16 0.95-4.94
48+ 2.62 1.15-5.95
ME Never 1.00
1-12 0.43 0.11-1.65
13-48 1.46 0.62-3.45
48+ 0.57 0.18-1.79
aAdjusted for age at first term birth, age at menarche, menopausal
status, history of benign breast disease and a family history of breast
cancer.
important hormonal component; age at menarche and at
first term pregnancy as well as castration appear to affect the
risk. Since the risk is increasingly elevated the longer the
period between menarche and first term pregnancy, exposure
to endogenous oestrogens may be part of the aetiological
process (Korenman, 1980). It seems entirely possible, there-
fore, that exogenous exposure to OCs during this period
could have an effect that such exposure does not have later in
life. It is clear from many studies with long term follow up
that exposure to OCs later in a woman's life has no effect
on breast cancer risk. Indeed in our data OC use only after
first prgenancy is associated with a slight (but non-significant)
protective effect.
However, since exposure at young ages, particularly before
first term pregnancy, is a relatively recent practice, few data
are available to evaluate any effect on breast cancer risk.
OCs became widely and freely available in the UK to
unmarried women in the early seventies. Such women will
now only be in their thirties and early forties and will be
unlikely to have accumulated long term early use more than
5 or 10 years ago. Since the formation of a palpable breast
cancer may typically take the best part of twenty years, (i.e.
the time for precancerous changes plus the time for a tumour
to be diagnosed) it may be too soon to expect to observe
a coherent epidemiological relationship (Armenian &
Lilienfeld, 1979; McPherson et al., 1986).
A parallel might, perhaps, be drawn with young women
exposed to radiation from the atomic bombs of Hiroshima
and Nagasaki who showed a dose related increase in breast
cancer incidence but not until 15-20 years after exposure
(Tokunaga et al., 1979) or, equally, with pregnant women
exposed to diethylstilboestrol who have been shown to have
twice the ultimate breast cancer risk compared with
unexposed controls (with a follow-up extending to forty
years), but in whom no differences were observed until 22
years after exposure (Greenberg et al., 1984). In the light of
the evidence reported here the overall results for long term
use before first pregnancy may be regarded as suggestive of
an effect.
It is, therefore, important to look for clues as early as
possible so that hypotheses suggested in one study as an
explanation for the diverse epidemiological results, can be
closely, quickly and independently investigated in others. For
this reason we have drawn attention to our findings which
suggest (but not strongly) a possible effect modification by
synthetic oestrogen type. The data also suggest (but not
strongly) a latent interval of at least ten years for E-O pills
between long term early exposure and an increased risk of
breast cancer diagnosis. However, the nature of these
findings is such that they should be taken as hypothesis
generating, as opposed to hypothesis testing. A priori, bothEARLY ORAL CONTRACEPTIVES AND BREAST CANCER 659
Table X Adjusteda relative risk of breast cancer associated with OC use before first term
pregnancy after excluding all such use within the stated period before diagnosis (or
equivalent date for controls)
Accumulated months use before
first term pregnancy more than
X years before diagnosis x2
Exclusion period
years Pill Trend Heterogeneity
X type Never 1-12 13-48 48+ 1 df 3 df
0 All 1.00 1.02 1.97 2.59 6.96 8.69
E-O 1.00 1.21 2.16 2.62 6.93 7.14
ME 1.00 0.43 1.46 0.57 0.04 3.31
2 All 1.00 1.17 1.78 2.46 6.47 6.75
E-O 1.00 1.07 2.54 2.92 6.86 6.96
ME 1.00 0.59 1.37 0.58 0.04 3.31
4 All 1.00 1.17 1.73 2.43 6.16 6.50
E-O 1.00 1.13 2.30 3.09 7.04 7.14
ME 1.00 0.59 1.37 0.58 0.04 3.31
6 All 1.00 1.24 1.83 2.30 6.28 6.55
E-O 1.00 1.30 1.93 3.69 7.14 7.52
ME 1.00 0.43 1.46 0.58 0.04 3.31
8 All 1.00 1.01 2.23 2.33 6.76 7.42
E-O 1.00 0.95 2.69 4.52 7.71 7.79
ME 1.00 0.59 1.62 0.63 0.01 3.90
10 All 1.00 1.20 2.45 1.65 5.61 7.93
E-O 1.00 1.74 3.20 5.65 8.97 9.00
ME 1.00 0.61 2.22 0.27 0.01 5.51
12 All 1.00 1.46 2.54 2.03 4.15 4.91
E-O 1.00 2.15 3.50 4.20 6.65 6.70
ME 1.00 1.04 2.34 0.22 0.25 3.95
14 All 1.00 1.74 1.37 1.97 2.25 2.35
E-O 1.00 1.78 2.05 3.43 2.72 2.74
ME 1.00 1.68 1.16 0.52 0.34 0.82
aAdjustments as before.
pill type and latency could plausibly be related to the
apparent discrepancies in published epidemiological results.
However, we decided to divide pill types into those
containing E-O and those containing ME because this was
the simplest data derived categorization we could make. We
are, nonetheless, impressed by the fact that the chi square
value in Table X for E-O pills did not diminish, in spite of
decreasing numbers as the exclusion period increased.
If either of these hypotheses is true, then the power with
which they can be reliably detected even in very large studies
is currently limited. All recent studies lack adequate
precision for detecting a latent effect, for in this study, for
instance, only two cases and one control had been exposed
for more than 4 years before first term pregnancy more than
15 years before diagnosis. Moreover pill type is probably
poorly recalled in the distant past and attention to any
subgroup of OCs reduces precision still further. If pill use at
particular times in a woman's life, for example when
anovulatory cycles are more common, is also important then
such complications reduces precision yet again. It is therefore
essential to pool data from different studies taking these
aspects ofpill use into account.
When these results are compared with those we have
published previously from a similar case-control study
(Vessey et al., 1982) but which was negative, the following
differences should be born in mind. First, recruitment to the
earlier study was completed in 1980 so there was a relatively
short maximum time between first OC exposure and
diagnosis. Secondly, early OC use was less common in the
Sixties than in the Seventies. Accordingly, long durations of
OC use before first term pregnancy were much less common
in the first study. In the earlier study, 13% of cases and
controls under the age of 40 had used OCs before first term
pregnancy, compared with 44% in this study. Moreover, of
this use in the earlier study 2% was for more than a year
more than ten years before diagnosis (or the equivalent date
for controls) compared with 11% in this study. Finally, in
the first study a larger proportion of such OC use was of
ME pills, because these were more common in the 1960's.
The notion of a latent effect is consistent with the known
epidemiology of breast cancer and with the observed effect
of radiation and diethylstilboestrol exposure. However, the
possibility of a different effect of the two synthetic
oestrogens has little basis in either theory or in empirical
observation. Mestranol is demethylated to E-O (Bolt et al.,
1974) which could give rise to lower peak plasma
concentrations of active oestrogen in women taking ME
containing pills than in those taking E-O containing pills
(Orme et al., 1983). Conceivably this could explain their
lesser effect on breast cancer risk. It is just as likely,
however, that the effect is a consequence of ME and E-O
being correlated with some other aspect of pill composition.
More endocrinological work is required, as well as
observational confirmation before any action is taken on
these findings. It should be noted that none of our data
directly incriminate modern low dose E-O containing pills in
any case.
Taking our results together with the extent of the bias
that can be a consequence of plausible latent intervals
(McPherson et al., 1986) and a possible effect modification
of pill type, it is possible that epidemiological studies are
emerging with consistent results. Young women in the US
apparently started using OCs around five years later than
their British counterparts (Anonymous, 1985) and a much
higher porportion of OCs in the CASH study contained
mestranol (Sattin et al., 1986).
We need to know whether these suggestions can be refuted
by other well conducted studies. In particular studies can
only now be begun among women with a relatively high risk
of breast cancer with a substantial amount of early OC use,660 K. McPHERSON et al.
sufficiently long ago. While it is clear that the latency
argument cannot easily explain the difference between our
latest results and the study from New Zealand (Paul et al.,
1986) it remains unclear whether or not some aspect of pill
type or formulation might not be the explanation. The
Scandinavian workers investigated a latent effect but their
analyses, which seemed to show no evidence for such an
effect, is not conclusive (McPherson & Drife, 1986). This is
because they investigated only time since first use, which is
clearly correlated with a possible latent period associated
with a particular exposure, but does not measure it.
Moreover, they adjusted for total OC exposure in their
analysis which might adjust out a latent effect because
duration of exposure likewise will be correlated with any
latent period. Recent correspondence suggests that the
differences observed between Norway and Sweden could be
attributed to more recent early use in Norway (Ronstam &
Olson, 1987).
The best way to proceed is to investigate some of these
hypotheses in independent data sets, to continue with the
assiduous collection of epidemiological data in which
contraceptive histories are carefully recorded and, as far as
possible, validated and to pool all data sets as soon as is
feasible (Vessey et al., 1983). It remains quite possible that
different OC formulations taken at different times in a
woman's reproductive life may have quite different, but
important, effects on breast cancer risk.
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